Exicure, Inc.

Contributing Author

Recent Articles by Exicure, Inc.

Jun-30	Exicure Announces Board and Committee Changes XCUR -5.45% GlobeNewswire
Jun-10	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement XCUR GlobeNewswire
Jun-01	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q XCUR XCUR -6.61% GlobeNewswire
Apr-22	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) XCUR GlobeNewswire
Apr-02	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions XCUR GlobeNewswire
Mar-25	Exicure, Inc. Reports Full Year 2025 Financial Results XCUR GlobeNewswire
Mar-25	Exicure, Inc. Reports Full Year 2025 Financial Results XCUR GlobeNewswire
Feb-05	Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant XCUR GlobeNewswire
Jan-21	Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings XCUR GlobeNewswire
Dec-08	Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting XCUR +8.78% XCUR +36.77% GlobeNewswire
Nov-07	Exicure, Inc. Reports Third Quarter 2025 Financial Results XCUR -6.82% GlobeNewswire
Nov-03	New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting XCUR GlobeNewswire
Oct-06	Exicure Highlights Recent Achievements and Near-term Strategic Priorities XCUR GlobeNewswire